2023 World Conference on Lung Cancer (Posters)-P1.11. DYNAMALK: Dynamic ctDNA Profiling in ALK+ NSCLC. A Study of the Australian Registry and Biobank of Thoracic Cancers AURORA

P1.11. DYNAMALK: Dynamic ctDNA Profiling in ALK+ NSCLC. A Study of the Australian Registry and Biobank of Thoracic Cancers AURORA - PDF(Abstract)

Back to course

Pdf Summary

The study titled "DYNAMALK: Dynamic ctDNA Profiling in ALK NSCLC" is focused on understanding the genetic characteristics of anaplastic lymphoma kinase rearranged (ALK) non-small cell lung cancer (NSCLC) and its response to different treatments. The aim of the study is to optimize patient treatment and survival by using real-time circulating tumor DNA (ctDNA) profiling to inform personalized drug selection.<br /><br />The study is being conducted as part of the Australian Registry and Biobank of Thoracic Cancers (AURORA) platform, by the Thoracic Oncology Group of Australasia (TOGA). It involves collecting blood samples at various stages of the patient's journey for dynamic ctDNA testing. The study will describe and correlate ctDNA findings with clinical outcomes, identify resistance patterns, and assess the impact of real-time ctDNA data on clinical management.<br /><br />There are two arms in the study. Arm A is focused on treatment-naïve patients and is supported by an Investigator Initiated Study grant from Pfizer Global. Arm B is for pre-treated patients and is funded by consumer-led philanthropic donation. Guardant Health is providing subsidised real-time ctDNA assays for the study.<br /><br />The study will provide valuable information on the utility of ctDNA profiling in selecting the best treatment and monitoring treatment response in ALK NSCLC patients. It will also contribute to the understanding of drug resistance patterns in this population.<br /><br />This study represents an important step in advancing personalized medicine for ALK NSCLC, as it aims to move beyond a sequential empiric monotherapy approach and provide real-world evidence on the outcomes of ALK inhibitors based on broader molecular resistance profiles. The study findings will inform clinical practice and may have implications for reimbursement decisions.<br /><br />Keywords: ALK NSCLC, ctDNA, Drug Resistance<br /><br />This study is part of the "Tumor Biology - Translational Biology - Omics and New Technologies" session at the WCLC 2023 conference.

Asset Subtitle

Malinda Itchins

Meta Tag

Speaker Malinda Itchins

Topic Tumor Biology: Translational Biology - Omics and New Technologies

Keywords

DYNAMALK

ALK NSCLC

ctDNA profiling

clinical outcomes

resistance patterns

real-time ctDNA data

personalized medicine

drug resistance patterns

molecular resistance profiles

WCLC 2023 conference